A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02264639

A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug.

Status: 
Recruiting
Study Date: 
Wed, 10/01/2014 to Wed, 06/01/2016
Bone Marrow Disease(s): 
paroxysmal nocturnal hemoglobinuria (PNH)
Intervention: 
Drug: APL-2